Business UpdateJul 1, 2026, 07:01 AM
Ocular Therapeutix to Present at July 2026 Conferences
AI Summary
Ocular Therapeutix announced its participation in several upcoming scientific and investor conferences in July 2026. The company will present at the 9th Annual OIS Retina Innovation Summit and the ASRS 44th Annual Meeting, where it will share efficacy and safety results from the Phase 3 SOL-1 trial for OTX-TKI in neovascular age-related macular degeneration. Additionally, the Executive Chairman, President and CEO will engage in a fireside chat at the HC Wainwright 6th Annual Ophthalmology Virtual Conference.
Key Highlights
- Ocular Therapeutix to participate in 9th Annual OIS Retina Innovation Summit on July 14, 2026.
- Company to present at The American Society of Retina Specialists (ASRS) 44th Annual Meeting, July 15-18, 2026.
- Presentation on Intravitreal Axitinib Hydrogel (OTX-TKI) Phase 3 SOL-1 trial results at ASRS.
- Presentation on real-world anti-VEGF treatment utilization at ASRS.
- Executive Chairman, President and CEO Pravin U. Dugel to participate in a fireside chat.
- Fireside chat at HC Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026.
Price Impact
More from OCUL